CEO Executive AssistantMeetings with the FDA and EMA represent some of the most consequential interactions in a pharmaceutical company’s regulatory lifecycle. A well-prepared FDA meeting can clarify the development pathway for a critical program, align the company and the agency on the data needed to support approval, and build the relationship of trust that makes future regulatory interactions more productive. An unprepared meeting, by contrast, can leave critical questions unresolved, create misunderstandings about the agency’s expectations, and waste an opportunity that may take months to reschedule. The personal assistant who manages the preparation and logistics for a pharmaceutical CEO’s regulatory agency meetings contributes directly to the company’s most important regulatory relationships.
The CEO’s Role in FDA and EMA Meetings
Pharmaceutical CEOs are not always present in FDA or EMA meetings. Routine technical meetings are typically attended by the regulatory affairs team, medical team, and scientific staff, without CEO participation. But CEO attendance is often warranted or required at specific categories of regulatory meetings.
These include high-level strategic meetings where the company is seeking to establish a broad regulatory framework for a novel development program, meetings where the CEO’s presence signals the company’s commitment and seriousness to the agency, meetings at which senior FDA leadership or EMA committee leadership are present, and meetings that occur in the context of a challenging regulatory situation where relationship management is important.
The PA manages the CEO’s regulatory meeting calendar with awareness of which meetings warrant CEO attendance and ensures that the CEO is appropriately prepared for each interaction.
The Meeting Request Process
FDA meetings are requested through a formal process that requires submission of a meeting request letter describing the meeting type (Type A, B, or C), the questions to be addressed, and the proposed agenda. EMA meetings are requested through similar formal channels. The timing of meeting requests relative to submission timelines and other regulatory activities requires coordination with the regulatory affairs team.
The PA works with the regulatory affairs team to ensure that meeting requests for CEO-attended meetings are submitted on schedule, that the meeting request documents accurately reflect the CEO’s questions and objectives, and that the administrative logistics of the meeting request process are managed appropriately.
For meetings with the FDA that occur at the FDA’s facilities in Silver Spring or Rockville, Maryland, the PA coordinates travel arrangements including transportation, lodging if overnight is required, and the specific logistics of arriving at FDA campus facilities.
Pre-Meeting Preparation
FDA and EMA meetings are prepared intensively. The agency receives a briefing document from the company at least four weeks before the meeting (for Type B meetings), which is reviewed by the relevant review division and used to prepare the agency’s questions and responses.
The CEO’s preparation for regulatory meetings typically includes several components. A scientific and regulatory briefing that covers the status of the program, the key questions being addressed in the meeting, the agency’s likely perspective on each question, and the company’s proposed answers. A strategy briefing that covers the company’s objectives for the meeting, any sensitive topics that may arise, and the negotiating parameters for key development questions. Rehearsal of the meeting’s interactive discussions, often conducted as a mock meeting with the regulatory team playing the role of the FDA reviewers.
The PA coordinates the logistics of this preparation process, scheduling briefing sessions and mock meetings at appropriate points in the preparation timeline, ensuring that materials are prepared and distributed to the CEO in advance of each preparation session, and managing any last-minute preparation needs that arise close to the meeting date.
EMA Meeting Logistics
EMA meetings present distinctive logistical challenges compared to FDA meetings. The EMA is headquartered in Amsterdam, requiring transatlantic travel for U.S.-based pharmaceutical companies. EMA committee meetings occur on fixed schedules and may require the CEO to be available in Amsterdam for several days around the meeting date.
The PA manages EMA meeting logistics including flights, hotel accommodations near the EMA’s Amsterdam Zuidas headquarters, ground transportation, and coordination with the company’s European regulatory affairs team. For meetings involving the Committee for Medicinal Products for Human Use (CHMP) or the Committee for Advanced Therapies (CAT), the PA ensures the CEO is briefed on the committee structure and the identities of the relevant rapporteur and co-rapporteur.
International Regulatory Meetings
Beyond the FDA and EMA, pharmaceutical companies with global development programs interact with regulatory agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and other major markets. The PA maintains awareness of the CEO’s international regulatory meeting calendar and coordinates travel and preparation logistics for these interactions with the relevant regional regulatory teams.
For companies developing products for the Chinese market, NMPA (National Medical Products Administration) meetings may require travel to Beijing or Shanghai and coordination with the company’s China regulatory team. These logistical demands are distinctive and require advance planning.
Post-Meeting Follow-Up
FDA and EMA meetings produce official meeting minutes that are sent by the agency to the company following the meeting. These minutes document the agreements reached, questions resolved, and any commitments made by either party during the meeting. The PA tracks the receipt of meeting minutes, ensures the CEO reviews them for accuracy, and coordinates with the regulatory team to manage any requests for clarification or correction.
Commitments made by the company during regulatory meetings must be tracked and fulfilled. The PA works with the regulatory affairs team to ensure that action items from regulatory meetings are tracked in the company’s regulatory action system and that the CEO is informed of any commitment that requires their follow-up.
For more on the full scope of PA responsibilities in pharmaceutical executive support, see pharma PA duties. The pharma CEO assistant guide provides additional context on supporting pharmaceutical executives through their most important regulatory interactions.
Conclusion
FDA and EMA meetings are high-stakes strategic events that require exceptional preparation and precise logistics management. The PA who manages these meetings effectively enables the CEO to arrive fully prepared, communicate the company’s position clearly, and advance the regulatory relationships that are essential to pharmaceutical development success. In an industry where regulatory strategy is often the critical path to patient access, this contribution has direct and meaningful impact on the company’s mission.
Related Reading
For further context, explore Personal Assistant for 3PL CEO Third Party Logistics: Operational Support for a High-Volume Industry and Personal Assistant for Abrasive Manufacturer CEO.